Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAG-M in Relapsed ALL
NCT01513603Phase 2Unknown
- Sponsor
- New York Medical College
- Start
- Jan 2012
- Primary completion
- Jan 2014
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine, cytarabine, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells, filgrastim in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), Burkitt leukemia, chronic myelogenous leukemia (CML), sponsored by New York Medical College. Status: unknown.
02
Drugs
cladribinecytarabinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cellsfilgrastim
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)Burkitt leukemiachronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT01513603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513603.